Companies that develop HIV drugs are at a standstill in bringing new medicines to market, Bloomberg reports. Of the 31 HIV meds on the market, only six were approved after 2004; Intelence was the last drug approved—and that was three years ago. The newest antiretrovirals are much safer and more effective, have fewer side effects and must be taken less frequently. As a result, the bar for bringing new drugs to market has gotten higher and fewer drugs are in the pipeline. This also means that HIV-positive people who develop drug resistance have fewer treatment options.
Source: Poz Magazine